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ARTICLE
Increased Sensitivity of the Neuronal Nicotinic Receptor a2
Subunit Causes Familial Epilepsy with Nocturnal Wandering
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Sleep has traditionally been recognized as a precipitating factor for some forms of epilepsy, although differential diagnosis
between some seizure types and parasomnias may be difﬁcult. Autosomal dominant frontal lobe epilepsy is characterized
by nocturnal seizures with hyperkinetic automatisms and poorly organized stereotyped movements and has been as-
sociated with mutations of the a4 and b2 subunits of the neuronal nicotinic acetylcholine receptor. We performed a
clinical and molecular genetic study of a large pedigree segregating sleep-related epilepsy in which seizures are associated
with fear sensation, tongue movements, and nocturnal wandering, closely resembling nightmares and sleep walking.
We identiﬁed a new genetic locus for familial sleep-related focal epilepsy on chromosome 8p12.3-8q12.3. By sequencing
the positional candidate neuronal cholinergic receptor a2 subunit gene (CHRNA2), we detected a heterozygous missense
mutation, I279N, in the ﬁrst transmembrane domain that is crucial for receptor function. Whole-cell recordings of
transiently transfected HEK293 cells expressing either the mutant or the wild-type receptor showed that the newCHRNA2
mutation markedly increases the receptor sensitivity to acetylcholine, therefore indicating that the nicotinic a2 subunit
alteration is the underlying cause. CHRNA2 is the third neuronal cholinergic receptor gene to be associated with familial
sleep-related epilepsies. Compared with the CHRNA4 and CHRNB2 mutations reported elsewhere, CHRNA2 mutations
cause a more complex and ﬁnalized ictal behavior.
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Epilepsy is a common and heterogeneous neurological dis-
order, with an estimated prevalence in European popu-
lations that ranges from 3 to 8 per 1,000 inhabitants.1,2
The genetic etiology is known in many epilepsies, but
speciﬁc gene mutations have been identiﬁed in only a
few epilepsy syndromes. These Mendelian epilepsies are
mainly channelopathies, and mutations in the genes en-
coding subunits of voltage-gated and ligand-gated ion
channels are responsible for the clinical phenotypes.3
Autosomal dominant nocturnal frontal lobe epilepsy
(ADNFLE [MIM 600513, 603204, and 605375]) is a clini-
cally distinct childhood-onset focal epilepsy that displays
clusters of sleep-related hypermotor seizures.4 ADNFLE is
associated with mutations in the genes encoding the a4
and b2 subunits of the neuronal acetylcholine receptor
(CHRNA4 and CHRNB2).5,6 The neuronal acetylcholine re-
ceptors (nAChRs) are pentameric ligand-gated ion chan-
nels distributed widely throughout the nervous system. So
far, 12 nAChR subunits have been identiﬁed (a2–a10 and
b2–b4).7 Each subunit spans the plasma membrane with
four transmembrane domains (M1–M4) and gives rise to
several different nAChR subtypes in the brain, based on
the subunit composition, all of which have their own
unique biochemical, pharmacological, and biophysical
characteristics.8 The nAChRs inﬂuence a wide range of
physiological functions, such as sleep, arousal, anxiety,
fatigue, and cognitive function. Furthermore, nAChR dys-
function is involved in a wide variety of diseases during
development, adulthood, and aging.7 The M2 and M3 do-
mains, which represent the ion-gating structure, are the
speciﬁc target of ADNFLE mutations, both in the a4 and
b2 subunit genes.9 In contrast, the ligand-bindingregion—
a complex and ﬂexible structure that includes a short do-
main directly linked to M110—localizes at the interface of
a and the adjacent subunit.7
We performed a clinical and molecular genetic study of
a family with seizures occurring during sleep and char-
acterized by arousal followed by a prominent fear sen-
sation, tongue movements, and nocturnal wanderings,
suggesting frontolimbic involvement. We localized the
genetic critical region and identiﬁed a missense mutation
in the neuronal cholinergic receptor a2 subunit gene
(CHRNA2) that affects the M1 domain of the receptor.
Electrophysiological studies of the mutant receptor
showed an increased sensitivity to the ligand.
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Figure 1. Pedigree structure and disease-haplotype segregation. Individuals available for typing are indicated by the generated
genotype data. The arrow indicates the proband. Blackened symbols denote individuals affected by epilepsy with nocturnal wandering
and ictal fear; unblackened symbols denote unaffected individuals. Circles and squares indicate females and males, respectively. Marker
order and distances in cM are given in table 2. The disease haplotype is boxed.
Subjects and Methods
Patients
We obtained clinical and genealogical information through a val-
idated questionnaire.11,12 All family members were personally ex-
amined (by C.M., T.P., and D.P.) Several seizures were recorded
during electroencephalograms (EEGs), were videotaped in the
proband, and were witnessed in the remaining affected family
members. All individuals included in the study gave written in-
formed consent. This study was approved by the ethical com-
mittees of the clinical institutions.
Genotyping and Linkage Analysis
Blood samples were obtained from 19 individuals (10 affected, 7
unaffected, and 2 spouses), and genomic DNA was isolated fol-
lowing standard procedures.13 We performed genomewide ge-
notyping, using a set of 382 ﬂuorescence-labeled polymorphic
microsatellite markers (Linkage Mapping Dye Set 2 [Applied Bio-
systems]) spanning the 22 autosomes at an average reciprocal
distance of ∼10 cM. An additional marker (D8S283) was added
for ﬁne mapping and haplotype analysis.
Data analysis was performed with the MLINK program (LINK-
AGE software package14) by assuming an autosomal dominant
disease with incomplete penetrance (0.90) and a disease-gene fre-
quency of 0.0001. The recombination frequencies (v) were con-
sidered to be equal between males and females. Speciﬁc marker-
allele frequencies were derived from the GDB Human Genome
Database.
Mutational Analysis
We determined the 8-exon genomic structure of CHRNA2 mRNA
(GenBank accession number NM_000742) by comparing its
2,664-bp sequence with the corresponding genomic sequence.
Exon-speciﬁc primers and PCR conditions are available on re-
quest. We performed mutation analysis, using direct DNA se-
quencing (DYEnamic ET Dye Terminator Kit [Amersham Biosci-
ences]); DHPLC analysis (Wave [Transgenomic]) of exonic
fragments, including intron-exon junctions; and direct DNA
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Table 1. Clinical Characteristics of Italian Family with Epilepsy with Nocturnal Wandering and Ictal Fear
Patient Sex
Age at
Onset
(years)
Age at
Follow-up
(years) Seizure Semiology
Seizure
Frequency
Precipitating
Factors EEG
II-1 F 5.5 80 Sudden awakening, vocalization or
grunting, hypermotor behavior
NK, still present NK NA
II-3 F 29 82 Sudden awakening, sitting on the
bed
NK NK NA
II-7 F 9 65 Sudden awakening, vocalization or
grunting, hypermotor behavior
NK, still present Coffee NA
III-3 F 15 42 Sudden awakening, frightening and
breathless sensations, thachycar-
dia and tongue paresthesia
Daily clusters NK R frontotemporal SW
III-4 M 9 39 Sudden awakening, frightening and
breathless sensation, wandering
with complex motor behavior
Daily clusters NK NA
III-6 F 10 42 Sudden awakening, frightening and
shivering sensations, tongue
protrusion, wandering
Hot weather Bilateral frontal SW
III-8 M 4.5 36 Sudden awakening followed by hy-
permotor behavior
Daily clusters Smoking cigarettes NA
III-10 F 6 25 Sudden awakening, vocalization or
grunting, hypermotor behavior
or wandering with complex
behavior
Weekly clusters Sudden noise,
hot weather
NA
IV-1 F 6 14 Sudden awakening, sitting on the
bed, hyperkinetic movements of
lower limbs
Daily clusters Sudden noise L frontal SW
IV-5a F 6 13 Sudden awakening, vocalization or
grunting, terriﬁed expression
and tongue protrusion
Daily clusters Hot weather L frontal spikes
NOTE.—L p left; NA p not available; NK p not known; R p right; SW p sharp waves.
a Proband.
Table 2. Two-Point LOD Scores for 8p21.2-8q12 Markers
Marker
LOD Score at v p
.00 .01 .05 .10 .20 .30 .40
D8S549 5.90 1.84 1.03 .64 .25 .08 .01
D8S258 3.33 .50 1.03 1.11 .94 .63 .29
D8S1771 1.56 1.53 1.41 1.25 .92 .58 .26
836TrA 3.26 3.21 3.01 2.73 2.09 1.35 .55
D8S283 .61 .61 .62 .59 .48 .33 .16
D8S505 .94 1.03 1.24 1.33 1.20 .84 .36
D8S285 2.01 2.00 1.94 1.81 1.42 .92 .37
D8S260 1.84 1.81 1.66 1.47 1.06 .61 .20
D8S270 9.56 3.86 1.80 .99 .34 .13 .06
sequencing (DYEnamic ET Dye Terminator Kit [Amersham
Biosciences]).
Constructs and Site-Directed Mutagenesis
We isolated human a2 (CHRNA2) and b4 (CHRNB4 [GenBank
accession number NM_000750]) nicotinic receptor cDNAs byPCR
ampliﬁcation of commercially available brain cDNA panels (BD
Biosciences Clontech cDNA Panels) and cloned them into the
expression vectors pcDNA3.1 (Invitrogen) and pcDNA3 (Invitro-
gen), respectively. To obtain an a2I279NpcDNA3.1 construct, we
introduced the 836TrA (I279N) mutation into the CHRNA2-
pcDNA3 (a2pcDNA3.1), using PCR-based site-directed mutagen-
esis (QuickChange site-directed mutagenesis kit [Stratagene])
with the following primers: 5′-TCCCCTGCCTGCTCAACTCCTG-
CCTCACTGTG-3′ (forward) and 5′-CACCGTGAGGCAGGAGTTG-
AGCAGGCAGGGGA-3′ (reverse). All constructs were sequence
veriﬁed.
Electrophysiology of the Mutant Channel
Cell culture and transfection procedure.—Either wild-type or mu-
tant a2 constructs were transiently cotransfected with the b4 sub-
unit (cDNA ratios were a2:b4 of 1:1, for wild-type receptors;
a2I279N:b4 of 1:1, for homozygous mutant receptor; and a2:
a2I279N:b4 of 1:1:2, for the simulated heterozygous state) into
HEK293 cells. For subsequent detection of cells expressing
nAChRs, an expression vector for the enhanced green ﬂuorescent
protein (E-GFP pcDNA3 [Clontech Laboratories]) was added to
the transfection mixture. The cell culture method and transfec-
tion procedure were reported elsewhere.15,16
Patch-clamp recording and data analysis.—At 36–48 h after trans-
fection, currents were recorded using thewhole-cell conﬁguration
of the patch-clamp method. Cells were voltage clamped at 60
mV with an Axopatch 200B ampliﬁer (Molecular Devices); cell
capacitance and series resistance were always compensated (75%–
85%) before each experiment. Pipette resistances were 2–3 MQ.
Currents were low-pass ﬁltered at 2 kHz and were acquired online
at 5–10 kHz with pClamp hardware and software (Molecular De-
vices). The extracellular solution contained 130 mM NaCl, 5 mM
KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, and 5 mM D-
glucose (pH 7.3). Stock solutions for nicotine and acetylcholine
were prepared fresh each week. The different ligand pipettes con-
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Figure 2. CHRNA2 mutation in familial epilepsy with nocturnal wandering and ictal fear. A, Electropherograms of CHRNA2 gene sequence
spanning the missense mutation in the proband (top) and a control (bottom). The arrow indicates the 836TrA transversion. B, DHPLC
elution proﬁle of the heterozygous proband (left) and a wild-type (wt) control (right). C, Evolutionary conservation of different a-
subunit I279 residues among different species (UniProtKB/Swiss-Prot).
tained 10 mM NaCl, 1.3 mM CaCl2, 2 mM MgCl2, 10 mM HEPES,
130 mM DL-aspartic acid potassium salt, 10 mM ethylene glycol-
bis(beta-aminoethyl ether)-N,N,N′,N′-tetraacetic acid, and 1 mM
Na-ATP (pH 7.3).
Currents were elicited by applying the ligand for 1–2 s to wild-
type, mutant, or simulated heterozygous receptors with an SF-
77B Perfusion Fast-Step system (Warner Instruments). During the
experiment, themaximal response (at 100 mMagonist)was always
tested at regular intervals, to exclude artifacts due to channel
rundown. Each ligand concentration was usually applied at least
2–3 times, and ∼120 s were left between subsequent applications,
to allow full receptor recovery from desensitization.
Data were analyzed ofﬂine by use of pClamp8 and Origin6
(Microcal) software. We generated dose-response curves to nic-
otine and acetylcholine by plotting average peak currents ob-
tained at the indicated ligand concentrations and normalized to
the current obtained in the presence of 100 mM agonist (np 6
for each concentration point). The experimental points were ﬁt-
ted with a single-term empirical Hill equation:
1
I ECL 50p 1 ,n{ [ ]}I (L)max
where L is the ligand, IL is the whole-cell current activated at a
certain L, is the maximal current (i.e., at mM), EC50I Lp 100max
is the L producing half activation, and n is the Hill coefﬁcient.
RT-PCR and Southern Blot Analysis
Human tissue was obtained from the Brain and Tissue Bank for
Developmental Disorders at the University of Maryland, Balti-
more. Brains from one male (16 years old, 16 h post mortem)
and one female (35 years old, 6 h post mortem) who had no
history of primary neurological or psychiatric disorders were pro-
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Figure 3. Electrophysiological properties of wild-type and mutant a2/b4 nicotinic receptors. Representative current traces evoked by
pulses of the indicated acetylcholine concentration for either a2/b4 (A) or a2I279N/b4 (B) nAChRs. Note the larger response in a2I279N/
b4 receptors at nonsaturating doses of agonist. The maximal response was always tested at regular intervals during the experiment,
to exclude artifacts due to channel rundown. Similar results were obtained with nicotine. No signiﬁcant difference was observed in the
current density of wild-type (a2/b4), mutant (a2I279N/b4), and heterozygous (a2a2I279N/b4) receptors, tested in the presence of 100
mM agonist. C and D, Dose-response curves to acetylcholine (C) and nicotine (D). Data points are average peak currents obtained at
the indicated ligand concentration and normalized to the current obtained in the presence of 100 mM agonist ( for eachnp 6
concentration point). The experimental points were ﬁtted with a single-term empirical Hill equation, providing the following estimates
for EC50: acetylcholine, 3.94  0.31 mM (for a2/b4) and 0.64  0.14 mM (for a2
I279N/b4); nicotine, 2.84  0.16 mM (for a2/b4),
0.52  0.07 mM (for a2I279N/b4), and 1.66  0.25 mM (for a2a2I279N/b4).
cessed as described elsewhere (Brain and Tissue Bank for Devel-
opmental Disorders Web site). Samples from the two brains were
dissected from exactly the same areas (brain cortex regions are
indicated by Brodmann areas): prefrontal (area 10), ventral pre-
frontal (area 11), anterior cingulate (area 32), insular (area 43),
temporal (area 21), parietal (area 4), occipital cortices (area 18),
putamen, caudate, amygdala, hippocampus, and thalamus.
Total RNA was puriﬁed from dissected tissues (Trizol [Invitro-
gen]) and was retrotranscribed with M-MLV reverse transcriptase
(Promega) in the presence of oligo-dT. PCR reactions were per-
formed for 22 cycles by use of AmpliTaq Gold polymerase (Perkin
Elmer) and gene-speciﬁc oligonucleotides designed across exons
(sequences available on request). Control reactions were per-
formed with samples without reverse transcription.
PCR products were electrophoresed on 1% agarose gels, were
blotted onto nylon ﬁlters, and were hybridized with 32P-labeled
CHRNA2-, CHRNA4-, CHRNB2-, and GAPDH-speciﬁc probes. Fil-
ters were exposed to BioMax ﬁlms (Kodak) for 5 min (GAPDH)
or 3 h (CHRNA2, CHRNA4, and CHRNB2).
Results
Patients and Pedigree
Clinical information was obtained from 24 individuals
across four generations of a Sardinian family (ﬁg. 1). Ten
family members had clusters of seizures exclusively during
sleep. Mean age at seizure onset was 10 years (median 7.5
years; range 4–29 years). The proband (IV-5) had episodes
with sudden awakening since age 6 years, vocalization
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Figure 4. Expression pattern of CHRNA2, CHRNA4, and CHRNB2
nicotinic subunits in human brain. For quantitative analysis of
different a and b subunits’ expression in the human brain, we
optimized a semiquantitative RT-PCR method coupled with South-
ern blot analysis. With this analysis, a relatively stronger expres-
sion was observed in the thalamus for CHRNA2 mRNA, whereas mild
expression was seen in the other brain regions analyzed for both
CHRNA2 and CHRNA4. CHRNB2 showed a homogeneous level of
expression throughout the different brain areas, with the excep-
tion of the temporal cortex. GAPDH was used as positive control.
RT- p negative control.
or grunting, fearful expression, and peculiar protrusive
movements of the tongue. Seizures lasted 20–30 s and
occurred in clusters of 2–4 attacks, usually while she was
falling asleep. The remaining affected familymembers had
nocturnal clusters of similar episodes including frighten-
ing, tingling, or shiver sensations; tongue movements;
and complex motor behaviors, such as walking outside
the room and descending the stairs (table 1). Clinical di-
agnosis in the older family members had been delayed
because nocturnal attacks had been interpreted as night-
mares and sleep walking.
Seizure frequency and severity varied within the family,
having a tendency to be more severe at onset, with oc-
currence of clusters of seizures every night in most pa-
tients. Complex motor behaviors and nocturnal wan-
derings were more frequent during childhood and
adolescence, whereas, from late adolescence through
adulthood, seizures occurred with weekly-to-monthly fre-
quency and were characterized by milder motor manifes-
tations. Only the two youngest affected individuals (IV-1
and IV-5) were seizure free while taking antiepileptic
drugs.
Linkage and Mutational Analysis
To map the genetic locus associated with this form of
sleep-related partial epilepsy, we performed a genomewide
linkage analysis. Markers on chromosome 8p21.2-8q12
showed signiﬁcant suggestive evidence of linkage to this
form (table 2). This wide region spans a genomic area of
60 cM between markers D8S258 and D8S270 and harbors
a cluster of neuronal cholinergic receptor genes (CHRNA2,
CHRNB3, and CHRNA6), encoding the a2, b3, and a6 sub-
units (UCSC Genome Browser).
Sequence analysis of the entire coding region of the a2
subunit revealed a heterozygous single-nucleotide substi-
tution (836TrA) in exon 6 of the proband (IV-5) (ﬁg. 2A).
This transversion leads to the substitution of a hydropho-
bic isoleucine at residue 279 with a polar asparagine
(I279N).
Denaturing high-performance liquid chromatography
(DHPLC) (ﬁg. 2B) and sequence analysis detected the pres-
ence of this mutation in all the affected family members
and in a phenotypically healthy individual (III-7), thus
suggesting incomplete penetrance for this disease. The
mutation was not found in 340 control chromosomes. The
I279 residue is invariant in nicotinic a subunits from dif-
ferent species (ﬁg. 2C), localizes to the ﬁrst transmembrane
domain (M1) of the a2 nAChR, and apparently does not
directly contribute to the structure of the ion gate.17
Electrophysiology of the Mutant Receptor
To test the electrophysiological behavior of the mutant
a2I279N nAChR subunit, we patch-clamped HEK 293
cells transiently coexpressing either a2/b4, a2I279N/b4, or
a2a2I279N/b4 receptor subunits. We ﬁrst analyzed the a2/
b4 and a2I279N/b4 receptors (ﬁg. 3A and 3B), and we ob-
served differences between these two types of receptors at
low concentrations of acetylcholine. a2I279N/b4 mutant re-
ceptor was activated by 0.3 mM acetylcholine challenge to
∼50% of the current evoked with saturating acetylcholine
(100 mM). On the contrary, the a2/b4 wild-type response
was ﬁvefold lower and displayed currents barely reaching
10% of maximal amplitude.
Determination of the dose-response curves to acetyl-
choline and nicotine over a broad range of agonist con-
centrations (ﬁg. 3C and 3D, respectively) showed that
a2I279N/b4 receptor has a signiﬁcantly higher sensitivity to
the natural agonist. Moreover, cells expressing both wild-
type and mutant receptors—thus mimicking the hetero-
zygous state—showed an intermediate response, as dem-
onstrated by the mean (SD) EC50 values for nicotinic
activation: 1.66  0.25 mM (for a2a2I279N/b4), 2.84 
0.16 mM (for a2/b4), and 0.52  0.07 mM (for a2I279N/b4)
(ﬁg. 3D).
The desensitization properties and channel permeabil-
ity were scarcely affected by the a2I279N mutation. The
monoexponential time constants of current decay in the
presence of 100 mM nicotine were 3.73  0.9 s for wild-
type, 4.72  0.97 s for heterozygous, and 5.14  0.98 s
for mutant receptors. In addition, the a2I279N mutation
produced minor variations in the receptor current re-
sponse to substitution of external sodium with potassium
and to the partial substitution of external sodium with 20
mM calcium (data not shown).
348 The American Journal of Human Genetics Volume 79 August 2006 www.ajhg.org
CHRNA2 Expression in Human Brain
Wide expression of nAChRs has been reported in primate
brain,18 including the a2 subunit.19 With the aim of con-
ﬁrming these data in humans, we examined the expres-
sion patterns of the a2, a4, and b2 focal epilepsy–causing
genes in distinct areas of post mortem human brain by
semiquantitative RT-PCR. a2 mRNA exhibited the highest
level of expression in the thalamus, but a diffuse expres-
sion was detected in the entire investigated sample, al-
though quantitative differences were identiﬁed among
cortical and subcortical areas. In particular, levels of ex-
pression of a2 transcripts in the isocortex (prefrontal, ven-
tral prefrontal, anterior cingulate, insular, temporal, su-
perior parietal, inferior parietal, and occipital cortex) were
rather homogeneous and of intermediate intensity be-
tween the thalamus, which had the highest signal, and
the hippocampus and subcortical nuclei, where a2 ex-
pression was moderate to weak (ﬁg. 4). a4 Subunit ex-
pression was similar to the a2 pattern, with the exception
of the thalamic sample where a2 transcript is considerably
more represented. In contrast, b2 mRNA was quite uni-
formly distributed throughout the different brain regions,
with the exception of temporal cortex, where the tran-
script was barely detectable.
Discussion
This study identiﬁes a new genetic locus on chromosome
8p12.3-8q12.3 for familial sleep-related focal epilepsywith
nocturnal wandering and ictal fear and establishes an as-
sociation with the nicotinic a2 subunit gene as the un-
derlying cause. Moreover, our results provide insight into
the pathological role of M1 domain mutation and of the
nicotinic a2 subunit in the CNS, conﬁrming that muta-
tions in nAChRs genes are involved in the epileptogenesis
related to sleep and arousal mechanisms.
The heteropentameric nicotinic receptor hosts two li-
gand-binding sites located in an extracellular domain di-
rectly linked to the amino-terminus of the M1 domain,
at the interface of a and ß subunits.20 Agonist binding at
these sites leads to the conformational changes operated
by M1 domain to the channel gate (M2 segment).21 In
fact, studies on the protein structure showed that most of
the M2 helix is probably separated from M1 and M3 by
water-ﬁlled space.17 However, few interhelices hydropho-
bic residues are strictly juxtaposed and crucial for the
transmission of the conformational change. Among these,
the F225 residue of the M1 segment of the Torpedo cali-
fornica a subunit closely contacts the L253 of the M2 seg-
ment.17 It is worth noting that the corresponding residue
in the a2 subunit of the human receptor is the evolu-
tionarily conserved I279 residue, which is mutated in
our patients. Recently, the ﬁrst M3 domain mutation
of the b2 subunit (I312M) was associated with epilepsy.9
It is intriguing that I312 of the human b2 subunit cor-
responds to I289 in the T. californica a subunit, a residue
in contact with L257 of the M2 domain17 and probably
interfering with the gating process. We propose that the
a2 subunit I279N mutation, which cosegregates with
the disease in our family, alters the relative movements
of the inner helices and outer shell during gating of the
receptor.
Therefore, the M1 mutation would inﬂuence the tran-
sition between the closed and open state of nAChR, rather
than altering agonist-binding sites, and would promote
the increased sensitivity of the mutant receptor. As a con-
sequence, neuronal cells harboring the mutant receptors
would respond to lower cholinergic stimuli.
While hypermotor manifestations of classical ADNFLE
result from activation of frontomesial and orbitofrontal
cortical areas,22 in the family described here, seizures are
also related to sleep but are manifested with prominent
fear and more-organized motor behaviors, such as noc-
turnal wanderings. These features are more in keeping
with frontolimbic and anterior cingulate involvement.23
Ictal single-photon emission CT studies suggest the role
of cingulated gyrus in sleep-arousal–related seizures with
prominent motor manifestations.23–25
Cholinergic neurons are known to exert a modulating
effect on sleep and arousal oscillations at thalamic and
cortical levels.26 Activation of the ascending cholinergic
system is associated with the abolition of spindle and slow
waves in the EEG and with enhancement of higher-fre-
quency activities, like natural waking.26 Neuronal nAChRs
seems to be expressed preferentially in the presynaptic
surface,27,28 thus regulating the release of acetylcholine or
other neurotransmitters, such as gamma-amino butyric
acid (GABA) and glutamate.29,30 In this way, they can pro-
duce an autosynaptic or heterosynaptic regulation. We
therefore hypothesize that an unbalanced excitation/in-
hibition circuitry, due to the mutant nicotinic receptor on
GABAergic reticular thalamic neurons, generates seizures
by facilitating synchronizing spontaneous oscillations in
thalamo-cortical connections.
Actually, the highest expression of CHRNA2 in the tha-
lamic area would further support this hypothesis and
could be consistent with epileptogenesis arising from net-
works that regulate arousal from sleep. However, it is dif-
ﬁcult to argue to what extent variations in the topographic
distributions of a4 and a2 might account for the peculi-
arity of ictal symptoms in this family, with respect to the
prominent aﬁnalistic hypermotor behavior that is most
often observed in ADNFLE.
Our results, besides increasing the number of genes im-
plicated in inheritable forms of epilepsy, strongly suggest
a pathogenetic role for the nicotinic a2 subunit in epilepsy
with nocturnal seizures characterized by fear and complex
motor behaviors. However, further studies are needed to
investigate whether mutations or common polymor-
phisms of the CHRNA2 gene represent a risk factor for
sleep-related epilepsies with similar semiology.
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Online Mendelian Inheritance inMan (OMIM), http://www.ncbi.
nlm.nih.gov/Omim/ (for ADNFLE)
UCSC Genome Browser, http://genome.ucsc.edu/ (for selecting
critical region candidate genes)
UniProtKB/Swiss-Prot, http://au.expasy.org/uniprot (for nicotinic
receptor subunit proteins alignment)
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